China Montelukast API Market Research Report By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, Others)- Forecast to 2035

China Montelukast API Market Overview:

As per MRFR analysis, the China Montelukast API Market Size was estimated at 67.5 (USD Million) in 2023. The China Montelukast API Market Industry is expected to grow from 90(USD Million) in 2024 to 250 (USD Million) by 2035. The China Montelukast API Market CAGR (growth rate) is expected to be around 9.733% during the forecast period (2025 - 2035).

Key China Montelukast API Market Trends Highlighted

Due to the rising incidence of respiratory diseases like asthma and allergic rhinitis in the general population, the China Montelukast API market is undergoing a number of noteworthy market trends. As China's healthcare programs concentrate on enhancing lung health, the demand for montelukast, which is frequently utilized for its anti-inflammatory qualities, has increased dramatically.
The need for efficient therapies like Montelukast is further fueled by government programs that seek to enhance air quality and address pollution-related public health issues. This market offers opportunities, especially for improving the domestic production capacity of Montelukast APIs. In keeping with its goal of dominating the global pharmaceutical market, China is bolstering its pharmaceutical manufacturing industry, which presents a great opportunity for regional producers to increase output and make investments in research and development for novel formulations. Innovative distribution methods and products that address the unique requirements of the Chinese consumer may result from partnerships between academic institutions and industrial participants.
There has been a recent trend toward stricter rules concerning API production procedures and quality requirements. Given China's evolving regulatory environment, adherence to safety and efficacy standards is of utmost importance.Furthermore, as more people look for online ways to buy their prescription drugs, the emergence of e-commerce platforms has increased patient access to Montelukast, propelling market expansion. These changes will cause the China Montelukast API market to change, offering chances as well as difficulties to those involved in the pharmaceutical sector.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

China Montelukast API Market Drivers

Rising Incidence of Allergic Diseases

The growing prevalence of allergic disorders such as asthma, allergic rhinitis, and other respiratory conditions is a significant driver for the China Montelukast API Market Industry. According to data from the Chinese Center for Disease Control and Prevention (CDC), asthma prevalence in China has increased from 3.5% in 2010 to approximately 5.0% in 2020, affecting over 45 million individuals. This rise indicates a growing need for effective medications such as Montelukast, which is recognized for its efficacy in alleviating symptoms associated with allergic conditions.Major pharmaceutical companies operating in China, like Beijing Novartis Pharma Co., Ltd., are well-positioned to benefit from this increasing demand by providing innovative formulations of Montelukast, thereby driving market growth.

Government Initiatives and Policies

The Chinese government has been actively implementing healthcare reforms aimed at improving access to essential medications. The State Council of China launched a significant initiative to enhance the production and pricing of key therapeutic drugs, including Montelukast. This initiative has led to reduced costs and improved availability of the API to local manufacturers. The National Health Commission of China supports this effort by emphasizing the importance of affordability in pharmaceutical care.Enhanced government support is expected to positively impact the China Montelukast API Market Industry, encouraging increased local manufacturing and innovation in delivering these critical medications.

Advancements in Manufacturing Technology

Technological advancements in the production processes of pharmaceutical APIs have significantly impacted the China Montelukast API Market Industry. With the introduction of advanced techniques such as continuous manufacturing and process analytical technology, Chinese manufacturers are achieving higher efficiencies and reducing production costs. Reports from the Ministry of Industry and Information Technology indicate that investment in the pharmaceutical sector, including the production of APIs, has increased by 15% year-on-year, leading to enhanced capabilities for local producers.This progress positions China as a competitive player in the global market, ensuring a sustained growth trajectory for the Montelukast API segment.

China Montelukast API Market Segment Insights

Montelukast API Market Application Insights

The Application segment of the China Montelukast API Market plays a crucial role in catering to various respiratory and allergic conditions that have become prevalent in the region. The landscape of this market has evolved due to the rising incidence of asthma and allergic disorders, which are significant public health concerns in China. With a growing urban population and increasing environmental pollution, the prevalence of asthma has surged, leading to a greater demand for effective treatments such as Montelukast.
This segment serves as a critical component for patients managing their asthma, often resulting in improved quality of life and reduced healthcare costs associated with asthma exacerbations. Furthermore, allergic rhinitis also represents a substantial portion of this market, reflecting the need for effective management options in a climate where allergens are widely present. The rising awareness and diagnosis of allergic conditions have spurred demand for treatment options, creating opportunities for Montelukast to penetrate deeper into the market by addressing a wide spectrum of these conditions.
Bronchospasm, another important application area, underscores the growing need for efficacious bronchodilators and anti-inflammatory medications in patient populations with chronic respiratory conditions. Urticaria, characterized by hives and itching, further emphasizes the diversity within the Application segment, showcasing Montelukast's versatility in providing relief for various allergic symptoms beyond respiratory conditions. Other conditions that fall within this segment also highlight the adaptability of Montelukast in the therapeutic landscape.
Consequently, the growing understanding of the importance of effective treatment solutions for these conditions has established a promising growth trajectory for the China Montelukast API Market. As the market continues to advance, market growth will hinge on the increasing integration of Montelukast into treatment protocols for asthma, allergic rhinitis, and other related conditions. Strengthening healthcare infrastructure, enhancing patient education, and fostering research and development efforts in these areas will further underline the significance of the Application segment in addressing pressing health needs in China.
Rising healthcare expenditure and emphasis on preventive measures only serve to underpin the expanding opportunities within the Application segment. This scenario positions the China Montelukast API Market not only as a vital contributor to the healthcare landscape but also as a significant driver of improvement in health outcomes for the population.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

China Montelukast API Market Key Players and Competitive Insights:

The China Montelukast API market is characterized by a highly competitive landscape where multiple players strive for market share and dominance. Montelukast, a widely used medication for managing asthma and allergic rhinitis, has seen increased demand due to the rise in respiratory disorders across the region. The competitive dynamics of this market involve not only the production capacities of the manufacturers but also their compliance with regulatory frameworks, technological advancements, and pricing strategies.
As companies engage in research and development to create more efficient and cost-effective manufacturing processes, the market is becoming increasingly fragmented. The presence of both established firms and emerging players indicates a vibrant ecosystem ripe for innovation. Competition is often centered around product quality, cost efficiency, market access, and the ability to meet the needs of both domestic and international markets.Zhejiang Hisun Pharmaceutical has established a significant presence in the China Montelukast API market. The company's reputation is built on its ability to produce high-quality APIs that meet stringent regulatory requirements, making it a preferred partner for various pharmaceutical manufacturers.
A key strength of Zhejiang Hisun Pharmaceutical lies in its robust research and development capabilities, which enable the company to innovate and improve production processes continually. The firm has invested heavily in modern technologies and facilities that enhance its production efficiency, allowing for competitive pricing and scalability. By focusing on quality and leveraging advanced manufacturing techniques, Zhejiang Hisun Pharmaceutical has secured a notable foothold in the market, positioning itself as a reliable supplier for both domestic needs and export opportunities.
Guangdong Huanan Pharmaceutical has also carved a niche for itself in the China Montelukast API market, offering a range of key products that cater to the growing demand for respiratory therapeutic drugs. The company is recognized for its strategic initiatives, which include partnerships aiming at mutual growth through mergers and acquisitions, enabling it to expand its capabilities and market reach. With a strong focus on quality control and regulatory compliance, Guangdong Huanan Pharmaceutical has developed a reputation for delivering reliable and consistent products to its clients.
The firm has enhanced its market presence by establishing collaborations with other pharmaceutical companies, thereby enhancing its distribution network. By investing in significant production infrastructure and navigating the evolving market dynamics, Guangdong Huanan Pharmaceutical continues to strengthen its position as a key player in the Montelukast API segment within China.

Key Companies in the China Montelukast API Market Include:

• Zhejiang Hisun Pharmaceutical


• Guangdong Huanan Pharmaceutical


• Nantong Jiangshan Pharmaceutical


• Yichang Renfu Pharmaceutical


• Zhejiang Jiuzhou Pharmaceutical


• Hunan ErKang Pharmaceutical


• Shaanxi Hanjiang Pharmaceutical


• Hubei Wanbang Biopharmaceuticals


• Sichuan Kelun Pharmaceutical


• Jiangsu Hengrui Medicine


• Lianhuan Pharmaceutical


• Dandong Yichuang Pharmaceutical


• Hubei Zhonghua Pharmaceutical


• Beijing Tiantan Biological Products

China Montelukast API Market Industry Developments

In recent months, the China Montelukast API Market has seen notable developments. Zhejiang Hisun Pharmaceutical and Guangdong Huanan Pharmaceutical, along with other major players, are experiencing a growth phase attributed to increased demand for asthma and allergy medications. The Chinese pharmaceutical industry's expansion has resulted in increased valuations for companies like Nantong Jiangshan Pharmaceutical and Yichang Renfu Pharmaceutical, significantly impacting market dynamics. Notably, in September 2023, Hunan ErKang Pharmaceutical announced plans to enhance its manufacturing capabilities, indicating a focus on scaling production. Additionally, significant investments by Zhejiang Jiuzhou Pharmaceutical and Shaanxi Hanjiang Pharmaceutical highlight ongoing efforts to innovate and maintain competitive advantages in the market. There has been no publicly reported merger or acquisition activity involving the aforementioned companies in the Montelukast API sector recently. The market's growth is further supported by rising healthcare expenditures in China and the government's initiatives to boost domestic pharmaceutical manufacturing capabilities. In previous years, the increase in regulatory approvals also led to enhanced production and distribution channels, allowing companies like Hubei Wanbang Biopharmaceuticals and Sichuan Kelun Pharmaceutical to broaden their market reach significantly.

China Montelukast API Market Segmentation Insights

Montelukast API Market Application Outlook

• Asthma


• Allergic Rhinitis


• Bronchospasm


• Urticaria


• Others

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	67.5(USD Million)
MARKET SIZE 2024	90.0(USD Million)
MARKET SIZE 2035	250.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	9.733% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Zhejiang Hisun Pharmaceutical, Guangdong Huanan Pharmaceutical, Nantong Jiangshan Pharmaceutical, Yichang Renfu Pharmaceutical, Zhejiang Jiuzhou Pharmaceutical, Hunan ErKang Pharmaceutical, Shaanxi Hanjiang Pharmaceutical, Hubei Wanbang Biopharmaceuticals, Sichuan Kelun Pharmaceutical, Jiangsu Hengrui Medicine, Lianhuan Pharmaceutical, Dandong Yichuang Pharmaceutical, Hubei Zhonghua Pharmaceutical, Beijing Tiantan Biological Products
SEGMENTS COVERED	Application
KEY MARKET OPPORTUNITIES	Rising asthma prevalence, Increased demand for generics, Expansion in respiratory therapies, Growing respiratory-related research, Government healthcare initiatives
KEY MARKET DYNAMICS	growing asthma prevalence, regulatory environment changes, increasing chronic respiratory diseases, generic drug competition, rising healthcare expenditure
COUNTRIES COVERED	China